Physicians' Academy for Cardiovascular Education

Beyond statins: The role of ezetimibe in targeting residual risk

Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom

This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome

Video navigation menu

  • Impact of dual inhibition of cholesterol synthesis and absorption 01:27
  • IMPROVE-IT: results of ezetimibe on top of statin 02:47
  • Clinical evidence for LDL lowering supported by genetic studies 03:56
  • Long-term benefits of LDL-lowering: WOSCOPS 20-year follow-up 06:07
  • Options for optimal LDL/non HDL-C lowering 10:53
  • Summary 11:30

Educational information

The educational objectives of this symposum were to:

Disclosures

Professor Chris Packard, MD: R&D Director, NHS Greater Glasgow & Clyde Health Board, Honorary Professor of Vascular Biochemistry, University of Glasgow - Consultant Clinical Scientist, Dept of Biochemistry NHS Greater Glasgow & Clyde Health Board

Funding

This EBAC accredited symposium was funded by unrestricted educational grants received from Novartis, MSD, Amgen

View slides of this lecture